Cellular senescence as a key contributor to secondary neurodegeneration in traumatic brain injury and stroke.
Abstract
Traumatic brain injury (TBI) and stroke pose major health challenges, impacting millions of individuals globally. Once considered solely acute events, these neurological conditions are now recognized as enduring pathological processes with long-term consequences, including an increased susceptibility to neurodegeneration. However, effective strategies to counteract their devastating consequences are still lacking. Cellular senescence, marked by irreversible cell-cycle arrest, is emerging as a crucial factor in various neurodegenerative diseases. Recent research further reveals that cellular senescence may be a potential driver for secondary neurodegeneration following brain injury. Herein, we synthesize emerging evidence that TBI and stroke drive the accumulation of senescent cells in the brain. The rationale for targeting senescent cells as a therapeutic approach to combat neurodegeneration following TBI/stroke is outlined. From a translational perspective, we emphasize current knowledge and future directions of senolytic therapy for these neurological conditions.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper discusses cellular senescence as a contributing factor to secondary neurodegeneration following traumatic brain injury and stroke, which aligns with the broader context of aging and age-related diseases. It explores the potential of targeting senescent cells as a therapeutic approach, indicating a focus on addressing underlying mechanisms rather than merely treating symptoms. However, while the findings are solid and contribute to the understanding of neurodegeneration in the context of aging, the impact is limited as it primarily synthesizes existing evidence rather than presenting groundbreaking new data or insights.
Author of this paper? Send a correction.